LYTIR

Insider · SEC Form 4 · President/CEO and Board Chair

Azamian Bobak R.

In the 12 months to Nov 19, 2026, on the open market: sold $3.1M of TARS. Filed a median of 2 business days after the trade.

Open-market purchases and sales this filer reported on SEC Form 4, by the day traded. Insiders have two business days to file. A sale marked 10b5-1 was made under a plan adopted in advance. How to read these

Insider purchases and sales, by month (last 12 months)Insider purchases: $0 in total; Insider sales: $3.1M in total.Jun: Insider sales $615KSep: Insider sales $1.7MNov: Insider sales $803KDecJanFebMarAprMayJunJulAugSepOctNov$1.7M
Insider purchases above the line: $0Insider sales below: $3.1M
Dollar value of open-market purchases and sales reported on SEC Form 4, by the month traded. Sales include pre-arranged 10b5-1 plan sales.
  1. TARSSold: Tarsus Pharmaceuticals, Inc. Nov 13, 2026 10,000 shares filed Nov 17, 2026 817,991 shares held indirectly after, as filed 10b5-1 plan filing $803K
  2. TARSSold: Tarsus Pharmaceuticals, Inc. Sep 4, 2026 10,000 shares filed Sep 9, 2026 2 transactions 10b5-1 plan filing $906K
  3. TARSSold: Tarsus Pharmaceuticals, Inc. Sep 2, 2026 10,000 shares filed Sep 3, 2026 837,991 shares held indirectly after, as filed 10b5-1 plan filing $801K
  4. TARSSold: Tarsus Pharmaceuticals, Inc. Jun 17, 2026 10,000 shares filed Jun 22, 2026 2 transactions 10b5-1 plan filing $615K

Source: SEC Form 4 filings. Value is shares × the price reported on the filing; a filing whose price failed Lytir's check against the market price is left out, and a trade that related owners reported on separate forms is counted once. Filings can be late, amended or wrong at the source; see methodology.

Planned sales (Form 144)

A Form 144 is filed before an insider sells restricted stock. It states an intent; the sale, if it happens, appears later on a Form 4. Notices filed under this filer's SEC CIK in the same 12 months, newest first; the figure is the market value the notice states. Not every notice becomes a sale. Every recent notice

  1. TARSBobak Azamian filed Nov 13, 2026 Tarsus Pharmaceuticals, Inc. Officer 10,000 shares planned sale date 11/13/2026 filing $802K